Doing the Moonwalk for fun and money

November 01, 2017

The annual Moonwalk began late on Saturday in Hyde Park, central London and arrived back from about 0600 BST on the following morning.

Celebrities, TV presenter Lorraine Kelly and model Nell McAndrew were among those on the Playtex Moonwalk.

The now annual event began in 1998 and was founded by Nina Barough who has herself suffered from breast cancer.

Ms Kelly says that breast cancer is something that touches so many as everyone has a relative or a close friend who has had it.

The event which aims to raise as much cash as possible while having fun at the same time, is according to Kelly ' fantastic'.

"But when we added the sex of the patient into the analysis we found a statistically higher proportion of men (5.82 times) than women received adjuvant radiotherapy, even when these other predictive factors were accounted for. We also found men were more likely to have adjuvant hormonal therapy then women, but that was because there was a higher proportion of men who had oestrogen-positive tumours. An equal proportion of men and women (one-quarter) received chemotherapy."

The breast cancer survival rates were 89% and 81% at 5 and 10 years for men and 88% and 79% for women. There was no difference between male and female breast cancer survival whether or not radiotherapy had been given.

Overall survival was 75% and 53% for men at 5 and 10 years and 82% and 65% for women. There was no difference in survival between men and women who had received radiotherapy, but men who had received no radiotherapy had poorer overall survival than women receiving no radiotherapy.

The reasons for giving, or withholding radiotherapy appeared to be different for men and women ?? men being withheld radiotherapy when they had poorer outlook than women and women being withheld radiotherapy when they had a better outlook.

"Said Dr Macdonald "A key finding is that males who did not receive radiotherapy had poorer overall survival than females. Given that breast cancer-specific survival was equivalent between these two groups, this suggests that co-morbidity rather than good prognostic factors was a major reason for not giving radiotherapy in males.

"We could find no evidence that gender is a prognostic factor for loco-regional relapse-free, breast cancer specific or overall survival following mastectomy once known prognostic factors and delivery of adjuvant radiotherapy were accounted for. This suggests that males should receive adjuvant therapy following similar guidelines to females."